MET and non-small cell lung carcinoma: Abnormal activation of the MET pathway can promote the proliferation, invasion, and migration of cancer cells, and eventually lead to the growth and development of malignant tumors,[1] including MET 14 exon skipping mutation, gene amplification, and overexpression.[2–4] The incidence of MET exon 14 skipping mutation stands at 3% to 6%[5,6] in NSCLC, and 3% to 4%[5,7] in lung adenocarcinoma.